Literature DB >> 24675576

Hepatitis C virus replication compartment formation: mechanism and drug target.

Vineela Chukkapalli1, Glenn Randall2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24675576      PMCID： PMC7003645          DOI： 10.1053/j.gastro.2014.03.017

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  31 in total

1.  Protein kinase D negatively regulates hepatitis C virus secretion through phosphorylation of oxysterol-binding protein and ceramide transfer protein.

Authors:  Yutaka Amako; Gulam H Syed; Aleem Siddiqui
Journal:  J Biol Chem       Date:  2011-02-01       Impact factor: 5.157

2.  Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A.

Authors:  Sandra Ciesek; Eike Steinmann; Heiner Wedemeyer; Michael P Manns; Johann Neyts; Norbert Tautz; Vanesa Madan; Ralf Bartenschlager; Thomas von Hahn; Thomas Pietschmann
Journal:  Hepatology       Date:  2009-11       Impact factor: 17.425

3.  Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life.

Authors:  Jeremie Guedj; Harel Dahari; Libin Rong; Natasha D Sansone; Richard E Nettles; Scott J Cotler; Thomas J Layden; Susan L Uprichard; Alan S Perelson
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-19       Impact factor: 11.205

4.  Oxysterol-binding protein family I is the target of minor enviroxime-like compounds.

Authors:  Minetaro Arita; Hirotatsu Kojima; Tetsuo Nagano; Takayoshi Okabe; Takaji Wakita; Hiroyuki Shimizu
Journal:  J Virol       Date:  2013-01-30       Impact factor: 5.103

5.  Hepatitis C virus stimulates the phosphatidylinositol 4-kinase III alpha-dependent phosphatidylinositol 4-phosphate production that is essential for its replication.

Authors:  Kristi L Berger; Sean M Kelly; Tristan X Jordan; Michael A Tartell; Glenn Randall
Journal:  J Virol       Date:  2011-06-22       Impact factor: 5.103

6.  Viral reorganization of the secretory pathway generates distinct organelles for RNA replication.

Authors:  Nai-Yun Hsu; Olha Ilnytska; Georgiy Belov; Marianita Santiana; Ying-Han Chen; Peter M Takvorian; Cyrilla Pau; Hilde van der Schaar; Neerja Kaushik-Basu; Tamas Balla; Craig E Cameron; Ellie Ehrenfeld; Frank J M van Kuppeveld; Nihal Altan-Bonnet
Journal:  Cell       Date:  2010-05-28       Impact factor: 41.582

7.  The role of the phosphatidylinositol 4-kinase PI4KA in hepatitis C virus-induced host membrane rearrangement.

Authors:  Andrew W Tai; Shadi Salloum
Journal:  PLoS One       Date:  2011-10-12       Impact factor: 3.240

8.  Role of oxysterol binding protein in hepatitis C virus infection.

Authors:  Yutaka Amako; Ali Sarkeshik; Hak Hotta; John Yates; Aleem Siddiqui
Journal:  J Virol       Date:  2009-07-01       Impact factor: 5.103

Review 9.  Profile of alisporivir and its potential in the treatment of hepatitis C.

Authors:  Philippe A Gallay; Kai Lin
Journal:  Drug Des Devel Ther       Date:  2013-02-15       Impact factor: 4.162

10.  Coxsackievirus mutants that can bypass host factor PI4KIIIβ and the need for high levels of PI4P lipids for replication.

Authors:  Hilde M van der Schaar; Lonneke van der Linden; Kjerstin H W Lanke; Jeroen R P M Strating; Gerhard Pürstinger; Erik de Vries; Cornelis A M de Haan; Johan Neyts; Frank J M van Kuppeveld
Journal:  Cell Res       Date:  2012-09-04       Impact factor: 46.297
View more
  1 in total

1.  Daclatasvir inhibits hepatitis C virus NS5A motility and hyper-accumulation of phosphoinositides.

Authors:  Vineela Chukkapalli; Kristi L Berger; Sean M Kelly; Meryl Thomas; Alexander Deiters; Glenn Randall
Journal:  Virology       Date:  2014-12-26       Impact factor: 3.616
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.